FDA Approved: LITHIUM CARBONATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for lithium carbonate by Hikma Pharmaceuticals USA Inc. under NDA 017812.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Lithium carbonate (Lithium carbonate)

Snippet

SUPPL AP for LITHIUM CARBONATE (LITHIUM CARBONATE)